As per the research report, the size of the Europe Biopharmaceutical Contract Manufacturing market is valued at USD 1.64 billion in 2021. It is expected to rise at a CAGR of 9.3% capping the market to USD 2.56 billion by 2026 during the forecast period 2021 to 2026.
Biopharmaceuticals are biological products that are made and developed to help with illness prevention and treatment. Recent advances in bio manufacturing and biotechnology have sparked the development of novel technologies capable of tackling the challenges associated with the production of biopharmaceuticals. As a result, the biopharmaceuticals contract manufacturing market is expanding.
The biopharmaceutical contract manufacturing market is primarily driven by the faster pace of production with contract manufacturing organizations, less cost than own manufacturing facilities, entry-level pharmaceutical production enterprises searching for investors. Furthermore, faster approvals for patent sharing, intellectual property copyright rules, higher demand for drugs by people, lower production capacity, and other factors are expected to boost the growth rate of the biopharmaceutical contract manufacturing industry. Instead of manufacturing every drug independently, they opt for contractual obligations with small companies to produce medicines through MOUs or investments.
Pharmaceutical companies see this as an opportunity to decrease their manufacturing costs by outsourcing these functions. As a result, production costs can be shifted to the research and development division, allowing for more efficient discoveries. Moreover, the rise of the biopharmaceutical contract manufacturing business presents an opportunity for CMOs in the form of mergers, acquisitions, and joint ventures with large corporations. These initiatives help CMOs see the possibilities for making their companies more financially secure and technologically adept.
The biopharmaceutical contract manufacturing market is constrained by several factors, including small enterprises' lack of technological knowledge in biopharmaceutical manufacturing, abuse of patent sharing details, and easy reverse engineering of the drug composition formula. These factors drive pharma behemoths to build their production facilities, putting the efficacy of contract manufacturing firms at risk. In addition, the lack of intellectual property restrictions in many countries and unrestricted patent rights in others also hinder contract manufacturing companies' market growth.
This research report on the Europe Biopharmaceutical Contract Manufacturing Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Therapeutic Area:
By Application:
By Country:
Geographically, the Europe held the second-largest share of the biopharmaceutical contract manufacturing market. The biopharmaceutical business in Europe is regulated by the European Medicines Agency and is subject to rigorous patent rights. The location has cutting-edge technologies for producing medications with maximum efficiency. Recommended new pharmaceuticals that enter the market after getting product clearance also significantly impact the market. The countries like Germany, France, the United Kingdom, Italy, Spain, and the rest of Europe, are expected to contribute to the European biopharmaceutical contract manufacturing market.
In recent years, there has been a slew of new entrants into the field of CMOS. This has allowed the major pharmaceutical companies to lessen the burden of developing and manufacturing each new medicine on their own in the European biopharmaceutical contract manufacturing market.
Moreover, the major players in the region are implementing various strategies to gain a competitive advantage over the marketplace. The techniques include mergers, partnerships, and acquisitions. For instance, Sanofi has contracted Boehringer Ingelheim to manufacture its biologics program. In addition, many businesses are turning to CMOs to expedite the development process and reduce production expenses.
Rentschler, which is trying to expand globally, added a new facility to its Laupheim, Germany, plant two years ago to increase capacity, citing the increased need for biologics.
KEY MARKET PLAYERS
Key players operating in the Europe Biopharmaceutical contract manufacturing market profiled in this report are Lonza Group AG, Baxter Biopharma Solutions, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH, Biomeva GmbH, Probiogen AG, Cytovance Biologics, Inc., KBI Biopharma, Inc., WuXi Biologics, Abzena Plc, Vetter Pharma International GmbH, Sandoz International GmbH, Catalent, Inc., AbbVie Contract Manufacturing (An AbbVie Company), Ajinomoto Althea Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 Insulin
5.1.3 Monoclonal Antibodies
5.1.4 Growth Factors
5.1.5 Interferons
5.1.6 Recombinant Protiens
5.1.7 Vaccines
5.1.8 Others
5.1.9 Y-o-Y Growth Analysis, By Product Type
5.1.10 Market Attractiveness Analysis, By Product Type
5.1.11 Market Share Analysis, By Product Type
5.2 Therapeutic Area
5.2.1 Introduction
5.2.2 Infectious Disease
5.2.3Cardiovascular Disease
5.2.4 Oncology
5.2.5 Metabolic Disease
5.2.6 Respiratory Disorder
5.2.7 Autoimmune Disease
5.2.8 Neurology
5.2.9 Ophthalmology
5.2.10 Others
5.2.11 Y-o-Y Growth Analysis, By Therapeutic Area
5.2.12 Market Attractiveness Analysis, By Therapeutic Area
5.2.13 Market Share Analysis, By Therapeutic Area
5.3 Application
5.3.1 Introduction
5.3.2 Clinical
5.3.3 Commercial
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.3.3 By Therapeutic Area
6.1.3.4 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.4.3 By Therapeutic Area
6.1.4.4 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.1.5.3 By Therapeutic Area
6.1.5.4 By Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Patheon N.V.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2Rentschler Biotechnologie GmbH
8.3 AbbVie Contract Manufacturing (An AbbVie Company)
8.4 Biomeva GmbH
8.5 Boehringer Ingelheim GmbH
8.6 WuXi Biologics
8.7 Abzena Plc
8.8 Lonza Group AG
8.9 Samsung Biologics Co.
8.10 Ajinomoto Althea, Inc.
8.11 Fujifilm Diosynth Biotechnologies
8.12 Probiogen AG
8.13 Sandoz International GmbH
8.14 KBI Biopharma, Inc.
8.15 Baxter Biopharma Solutions
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
